Chinese Journal of Tissue Engineering Research ›› 2025, Vol. 29 ›› Issue (1): 175-184.doi: 10.12307/2024.728

Previous Articles     Next Articles

Long non-coding RNA directly or indirectly affects osteoporosis through p38MAPK signaling pathway

Qin Hao1, Kang Teng1, Liu Gang2   

  1. 1Clinical College of Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou Province, China; 2Department of Orthopedics, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou Province, China
  • Received:2023-10-17 Accepted:2023-11-21 Online:2025-01-08 Published:2024-05-20
  • Contact: Liu Gang, MD, Chief physician, Department of Orthopedics, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou Province, China
  • About author:Qin Hao, Master candidate, Clinical College of Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou Province, China
  • Supported by:
    2022 Doctoral Research Starting Fund of Affiliated Hospital of Guizhou Medical University, No. gyfybsky-2022-43 (to LG)

Abstract: BACKGROUND: In recent years, numerous studies have found that long non-coding RNA is involved in the occurrence and development of osteoporosis. p38MAPK signaling pathway is involved in the differentiation of bone marrow mesenchymal stem cells, osteoblasts and osteoclasts, and participates in the development of osteoporosis. LncRNA can directly or indirectly participate in the occurrence and development of osteoporosis by affecting the p38MAPK signaling pathway. 
OBJECTIVE: To review the effect of long non-coding RNA directly or indirectly on the progression of osteoporosis through the p38MAPK signaling pathway, and to provide a new idea for long non-coding RNA in the prevention and treatment of osteoporosis. 
METHODS: PubMed, CNKI, and Wanfang databases were searched with “long non-coding RNA, osteoporosis, mesenchymal stem cells, osteoblasts, osteoclasts, p38 signaling pathway” as the Chinese and English search terms. Old, repeated and low-credibility views were excluded. The retrieved literature was summarized, summed up, and analyzed. Seventy-six representative articles were selected.
RESULTS AND CONCLUSION: (1) Long non-coding RNA participates in the prevention and treatment of osteoporosis through a variety of ways, including promoting the osteogenic differentiation of bone marrow mesenchymal stem cells, promoting the differentiation and secretion activity of osteoblasts, inhibiting the proliferation and bone resorption of osteoclasts, and regulating the activation or inhibition of osteoblast-related cellular pathways. Activation of p38MAPK signaling pathway can delay the progression of osteoporosis, and inhibition of p38MAPK signaling pathway can inhibit the absorption of osteoclasts, thereby affecting the occurrence and development of osteoporosis. (2) The overexpression or low expression of the corresponding long non-coding RNA can affect the proliferation or differentiation of osteoblasts and osteoclasts through the p38MAPK signaling pathway, regulate the process of bone remodeling, and then affect the occurrence and development of osteoporosis. A large number of basic research results show that long non-coding RNA and p38MAPK signaling pathway may be potential application and clinical translation value in the treatment of osteoporosis. Moreover, the corresponding long non-coding RNA overexpression or low expression lentivirus, transfection plasmid, and the corresponding p38MAPK signaling pathway inhibitor have been confirmed to have targeted regulatory effects in vitro cell experiments and animal models. (3) Therefore, targeting long non-coding RNA and p38MAPK signaling pathways to regulate the differentiation and function of bone marrow mesenchymal stem cells or inhibiting the proliferation and differentiation of osteoclasts may provide an innovative therapeutic strategy to delay the progression of osteoporosis.

Key words: osteoporosis, long non-coding RNA, p38MAPK, mesenchymal stem cell, osteoblast, osteoclast, signaling pathway, bone remodeling, estrogen, bisphosphonates

CLC Number: